{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:28:23Z","timestamp":1794288503618,"version":"4.9.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"8056","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved over short timescales, leading to the emergence of more transmissible variants such as Alpha and Delta<jats:sup>1\u20133<\/jats:sup>. The arrival of the Omicron variant marked a major shift, introducing numerous extra mutations in the spike gene compared with earlier variants<jats:sup>1,2<\/jats:sup>. These evolutionary changes have raised concerns regarding their potential impact on immune evasion, disease severity and the effectiveness of vaccines and treatments<jats:sup>1,3<\/jats:sup>. In this epidemiological study, we identified two distinct patterns in the protective effect of natural infection against reinfection in the Omicron versus pre-Omicron eras. Before Omicron, natural infection provided strong and durable protection against reinfection, with minimal waning over time. However, during the Omicron era, protection was robust only for those recently infected, declining rapidly over time and diminishing within a year. These results demonstrate that SARS-CoV-2 immune protection is shaped by a dynamic interaction between host immunity and viral evolution, leading to contrasting reinfection patterns before and after Omicron\u2019s first wave. This shift in patterns suggests a change in evolutionary pressures, with intrinsic transmissibility driving adaptation pre-Omicron and immune escape becoming dominant post-Omicron, underscoring the need for periodic vaccine updates to sustain immunity.<\/jats:p>","DOI":"10.1038\/s41586-024-08511-9","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:05:48Z","timestamp":1738771548000},"page":"1024-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron"],"prefix":"10.1038","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-6968","authenticated-orcid":false,"given":"Hiam","family":"Chemaitelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-6657","authenticated-orcid":false,"given":"Houssein H.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0819-6103","authenticated-orcid":false,"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-2788","authenticated-orcid":false,"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Al Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Al-Kanaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-2713","authenticated-orcid":false,"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan F.","family":"Abdul-Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1038","authenticated-orcid":false,"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ghaith","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad Eid","family":"Al-Romaihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Al-Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-8253","authenticated-orcid":false,"given":"Abdullatif","family":"Al-Khal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bertollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"8511_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361\u2013379 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"8511_CR2","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41564-023-01504-w","volume":"8","author":"C Roemer","year":"2023","unstructured":"Roemer, C. et al. SARS-CoV-2 evolution in the omicron era. Nat. Microbiol. 8, 1952\u20131959 (2023).","journal-title":"Nat. Microbiol."},{"key":"8511_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41591-022-01836-w","volume":"28","author":"L Subissi","year":"2022","unstructured":"Subissi, L. et al. An early warning system for emerging SARS-CoV-2 variants. Nat. Med. 28, 1110\u20131115 (2022).","journal-title":"Nat. Med."},{"key":"8511_CR4","doi-asserted-by":"publisher","first-page":"e1003879","DOI":"10.1371\/journal.pmed.1003879","volume":"18","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med. 18, e1003879 (2021).","journal-title":"PLoS Med."},{"key":"8511_CR5","doi-asserted-by":"publisher","unstructured":"Abu-Raddad, L. J. et al. Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab909 (2021).","DOI":"10.1093\/cid\/ciab909"},{"key":"8511_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamainternmed.2021.7949","volume":"182","author":"AA Butt","year":"2022","unstructured":"Butt, A. A. et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern. Med. 182, 197\u2013205, (2022).","journal-title":"JAMA Intern. Med."},{"key":"8511_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","volume":"401","author":"Covid Forecasting Team.","year":"2023","unstructured":"Covid Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 401, 833\u2013842 (2023).","journal-title":"Lancet"},{"key":"8511_CR8","first-page":"100861","volume":"35","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinMed. 35, 100861 (2021).","journal-title":"EClinMed."},{"key":"8511_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556\u2013567 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"8511_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1056\/NEJMc2110300","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H., Bertollini, R., Abu-Raddad, L. J. & National Study Group for COVID Epidemiology. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N. Engl. J. Med. 385, 2585\u20132586 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJMc2214114","volume":"388","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Protection against reinfection with the omicron BA.2.75 subvariant. N. Engl. J. Med. 388, 665\u2013667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR12","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMc2209306","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. N. Engl. J. Med. 387, 1620\u20131622 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR13","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant. J. Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taae053 (2024).","DOI":"10.1093\/jtm\/taae053"},{"key":"8511_CR14","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taac109 (2022).","DOI":"10.1093\/jtm\/taac109"},{"key":"8511_CR15","doi-asserted-by":"publisher","unstructured":"Ayoub, H. H. et al. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. Am. J. Epidemiol. https:\/\/doi.org\/10.1093\/aje\/kwad239 (2023).","DOI":"10.1093\/aje\/kwad239"},{"key":"8511_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","volume":"386","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 386, 1288\u20131290 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85428-7","volume":"11","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233 (2021).","journal-title":"Sci. Rep."},{"key":"8511_CR18","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1016\/j.cell.2023.08.026","volume":"186","author":"M Bouhaddou","year":"2023","unstructured":"Bouhaddou, M. et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell 186, 4597\u20134614 e4526 (2023).","journal-title":"Cell"},{"key":"8511_CR19","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"8511_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol."},{"key":"8511_CR21","doi-asserted-by":"publisher","first-page":"1363045","DOI":"10.3389\/fmed.2024.1363045","volume":"11","author":"H Chemaitelly","year":"2024","unstructured":"Chemaitelly, H. et al. Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation. Front. Med. 11, 1363045 (2024).","journal-title":"Front. Med."},{"key":"8511_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.abf2946","volume":"371","author":"L du Plessis","year":"2021","unstructured":"du Plessis, L. et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science 371, 708\u2013712 (2021).","journal-title":"Science"},{"key":"8511_CR23","doi-asserted-by":"publisher","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https:\/\/doi.org\/10.1126\/science.abg3055 (2021).","DOI":"10.1126\/science.abg3055"},{"key":"8511_CR24","doi-asserted-by":"publisher","unstructured":"Luo, C. H. et al. Infection with the SARS-CoV-2 delta variant is associated with higher recovery of infectious virus compared to the alpha variant in both unvaccinated and vaccinated individuals. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab986 (2021).","DOI":"10.1093\/cid\/ciab986"},{"key":"8511_CR25","doi-asserted-by":"publisher","first-page":"984784","DOI":"10.3389\/fimmu.2022.984784","volume":"13","author":"SH Qassim","year":"2022","unstructured":"Qassim, S. H. et al. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. Front. Immunol. 13, 984784 (2022).","journal-title":"Front. Immunol."},{"key":"8511_CR26","doi-asserted-by":"publisher","first-page":"e000479","DOI":"10.1136\/bmjph-2023-000479","volume":"1","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar. BMJ Public Health 1, e000479 (2023).","journal-title":"BMJ Public Health"},{"key":"8511_CR27","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"8511_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38188-z","volume":"14","author":"J Ito","year":"2023","unstructured":"Ito, J. et al. Convergent evolution of SARS-CoV-2 omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 14, 2671 (2023).","journal-title":"Nat. Commun."},{"key":"8511_CR29","doi-asserted-by":"publisher","first-page":"eabq1841","DOI":"10.1126\/science.abq1841","volume":"377","author":"CJ Reynolds","year":"2022","unstructured":"Reynolds, C. J. et al. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure. Science 377, eabq1841 (2022).","journal-title":"Science"},{"key":"8511_CR30","doi-asserted-by":"publisher","first-page":"eadh0761","DOI":"10.1126\/sciadv.adh0761","volume":"9","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. History of primary-series and booster vaccination and protection against omicron reinfection. Sci. Adv. 9, eadh0761 (2023).","journal-title":"Sci. Adv."},{"key":"8511_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K Roltgen","year":"2022","unstructured":"Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040 e1014 (2022).","journal-title":"Cell"},{"key":"8511_CR32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","volume":"23","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect. Dis. 23, 816\u2013827 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"8511_CR33","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2211055 (2022).","DOI":"10.1056\/NEJMc2211055"},{"key":"8511_CR34","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","volume":"384","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N. Engl. J. Med. 384, 2259\u20132261 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR35","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A COVID-19 milestone attained - a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"8511_CR37","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1126\/science.add2897","volume":"377","author":"EJ Wherry","year":"2022","unstructured":"Wherry, E. J. & Barouch, D. H. T cell immunity to COVID-19 vaccines. Science 377, 821\u2013822 (2022).","journal-title":"Science"},{"key":"8511_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.chom.2024.01.010","volume":"32","author":"DM Altmann","year":"2024","unstructured":"Altmann, D. M. & Boyton, R. J. Arming up against omicron subvariants. Cell Host Microbe. 32, 147\u2013148 (2024).","journal-title":"Cell Host Microbe."},{"key":"8511_CR39","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMc2108120","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & National Study Group for COVID Epidemiology. Severity of SARS-CoV-2 reinfections as compared with primary infections. N. Engl. J. Med. 385, 2487\u20132489 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR40","doi-asserted-by":"publisher","first-page":"e1830","DOI":"10.1093\/cid\/ciaa1846","volume":"73","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Assessment of the risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting. Clin. Infect. Dis. 73, e1830\u2013e1840 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"8511_CR41","doi-asserted-by":"publisher","first-page":"104734","DOI":"10.1016\/j.ebiom.2023.104734","volume":"95","author":"HN Altarawneh","year":"2023","unstructured":"Altarawneh, H. N. et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMed. 95, 104734 (2023).","journal-title":"EBioMed."},{"key":"8511_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30895-3","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat. Commun. 13, 3082 (2022).","journal-title":"Nat. Commun."},{"key":"8511_CR43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S1473-3099(22)00409-1","volume":"22","author":"MM Higdon","year":"2022","unstructured":"Higdon, M. M. et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect. Dis. 22, 1114\u20131116 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"8511_CR44","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR45","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa2210058","volume":"387","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. COVID-19 vaccine protection among children and adolescents in Qatar. N. Engl. J. Med. 387, 1865\u20131876 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR46","first-page":"102102","volume":"62","author":"SH Qassim","year":"2023","unstructured":"Qassim, S. H. et al. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. EClinMed. 62, 102102 (2023).","journal-title":"EClinMed."},{"key":"8511_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860\u2013868 (2020).","journal-title":"Science"},{"key":"8511_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1126\/science.abe6522","volume":"371","author":"JS Lavine","year":"2021","unstructured":"Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 371, 741\u2013745 (2021).","journal-title":"Science"},{"key":"8511_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature01509","volume":"422","author":"NM Ferguson","year":"2003","unstructured":"Ferguson, N. M., Galvani, A. P. & Bush, R. M. Ecological and immunological determinants of influenza evolution. Nature 422, 428\u2013433 (2003).","journal-title":"Nature"},{"key":"8511_CR50","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/S2666-5247(21)00180-4","volume":"2","author":"MM Patel","year":"2021","unstructured":"Patel, M. M., York, I. A., Monto, A. S., Thompson, M. G. & Fry, A. M. Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. Lancet Microbe. 2, e715\u2013e725 (2021).","journal-title":"Lancet Microbe."},{"key":"8511_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijid.2023.09.005","volume":"136","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. Int. J. Infect. Dis. 136, 81\u201390 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"8511_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97606-8","volume":"11","author":"S Seedat","year":"2021","unstructured":"Seedat, S. et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Sci. Rep. 11, 18182 (2021).","journal-title":"Sci. Rep."},{"key":"8511_CR53","doi-asserted-by":"publisher","first-page":"e012291","DOI":"10.1136\/bmjgh-2023-012291","volume":"8","author":"AA AlNuaimi","year":"2023","unstructured":"AlNuaimi, A. A. et al. All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic. BMJ Glob. Health 8, e012291 (2023).","journal-title":"BMJ Glob. Health"},{"key":"8511_CR54","doi-asserted-by":"publisher","first-page":"104684","DOI":"10.1016\/j.meegid.2020.104684","volume":"88","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect. Genet. Evol. 88, 104684 (2021).","journal-title":"Infect. Genet. Evol."},{"key":"8511_CR55","doi-asserted-by":"publisher","unstructured":"Sukik, L. et al. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: a time-dependent gradient. Vaccine https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.026 (2024).","DOI":"10.1016\/j.vaccine.2024.04.026"},{"key":"8511_CR56","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR57","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","volume":"27","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med. 27, 1614\u20131621 (2021).","journal-title":"Nat. Med."},{"key":"8511_CR58","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMc2119432","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & National Study Group for COVID Vaccination. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 386, 1091\u20131093 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR59","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMc2117933","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & National Study Group for COVID Vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N. Engl. J. Med. 386, 799\u2013800 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Effects of previous infection and vaccination on symptomatic omicron infections. N. Engl. J. Med. 387, 21\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR61","doi-asserted-by":"publisher","first-page":"taad106","DOI":"10.1093\/jtm\/taad106","volume":"30","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections. J. Travel Med. 30, taad106 (2023).","journal-title":"J. Travel Med."},{"key":"8511_CR62","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J. et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N. Engl. J. Med. 386, 1804\u20131816 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8511_CR63","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","volume":"31","author":"ML Jackson","year":"2013","unstructured":"Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165\u20132168 (2013).","journal-title":"Vaccine"},{"key":"8511_CR64","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1016\/j.vaccine.2017.04.037","volume":"35","author":"JR Verani","year":"2017","unstructured":"Verani, J. R. et al. Case-control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls. Vaccine 35, 3295\u20133302 (2017).","journal-title":"Vaccine"},{"key":"8511_CR65","doi-asserted-by":"publisher","first-page":"112911","DOI":"10.1016\/j.envres.2022.112911","volume":"209","author":"S Pilz","year":"2022","unstructured":"Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R. & Ioannidis, J. P. A. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ. Res. 209, 112911 (2022).","journal-title":"Environ. Res."},{"key":"8511_CR66","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/01632787211047932","volume":"44","author":"N Kojima","year":"2021","unstructured":"Kojima, N., Shrestha, N. K. & Klausner, J. D. A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection. Eval. Health Prof. 44, 327\u2013332 (2021).","journal-title":"Eval. Health Prof."},{"key":"8511_CR67","doi-asserted-by":"publisher","first-page":"05005","DOI":"10.7189\/jogh.11.05005","volume":"11","author":"HH Ayoub","year":"2021","unstructured":"Ayoub, H. H. et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J. Glob. Health 11, 05005 (2021).","journal-title":"J. Glob. Health"},{"key":"8511_CR68","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.isci.2021.102646","volume":"24","author":"PV Coyle","year":"2021","unstructured":"Coyle, P. V. et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. iScience 24, 102646 (2021).","journal-title":"iScience"},{"key":"8511_CR69","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3201\/eid2705.204365","volume":"27","author":"A Jeremijenko","year":"2021","unstructured":"Jeremijenko, A. et al. Herd immunity against Severe Acute Respiratory Syndrome Coronavirus 2 infection in 10 communities, Qatar. Emerg. Infect. Dis. 27, 1343\u20131352 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"8511_CR70","doi-asserted-by":"publisher","first-page":"ofab221","DOI":"10.1093\/ofid\/ofab221","volume":"8","author":"MH Al-Thani","year":"2021","unstructured":"Al-Thani, M. H. et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open Forum. Infect. Dis. 8, ofab221 (2021).","journal-title":"Open Forum. Infect. Dis."},{"key":"8511_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32363-4","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Protection of omicron sub-lineage infection against reinfection with another omicron sub-lineage. Nat. Commun. 13, 4675 (2022).","journal-title":"Nat. Commun."},{"key":"8511_CR72","unstructured":"World Health Organization. Living Guidance for Clinical Management of COVID-19 https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2 (2023)."},{"key":"8511_CR73","unstructured":"World Health Organization. International Guidelines for Certification and Classification (Coding) of COVID-19 as Cause of Death https:\/\/www.who.int\/publications\/m\/item\/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death (2023)."},{"key":"8511_CR74","doi-asserted-by":"publisher","first-page":"768883","DOI":"10.3389\/fcimb.2021.768883","volume":"11","author":"FM Benslimane","year":"2021","unstructured":"Benslimane, F. M. et al. One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. Front. Cell Infect. Microbiol. 11, 768883 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"8511_CR75","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijid.2021.09.006","volume":"112","author":"MR Hasan","year":"2021","unstructured":"Hasan, M. R. et al. Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar. Int. J. Infect. Dis. 112, 52\u201354 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"8511_CR76","doi-asserted-by":"publisher","first-page":"145608","DOI":"10.1016\/j.scitotenv.2021.145608","volume":"774","author":"J Saththasivam","year":"2021","unstructured":"Saththasivam, J. et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. Sci. Total Environ. 774, 145608 (2021).","journal-title":"Sci. Total Environ."},{"key":"8511_CR77","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38, 1228\u20131234 (2009).","journal-title":"Commun. Stat. Simul. Comput."},{"key":"8511_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35815-7","volume":"14","author":"HF Tseng","year":"2023","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 14, 189 (2023).","journal-title":"Nat. Commun."},{"key":"8511_CR79","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1002\/sim.5879","volume":"32","author":"A Sjolander","year":"2013","unstructured":"Sjolander, A. & Greenland, S. Ignoring the matching variables in cohort studies \u2013 when is it valid and why? Stat. Med. 32, 4696\u20134708 (2013).","journal-title":"Stat. Med."},{"key":"8511_CR80","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud, M. J. & Hernan, M. A. Why test for proportional hazards? JAMA 323, 1401\u20131402 (2020).","journal-title":"JAMA"},{"key":"8511_CR81","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jama.2021.19623","volume":"326","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination. JAMA 326, 1930\u20131939 (2021).","journal-title":"JAMA"},{"key":"8511_CR82","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1016\/S2666-5247(22)00287-7","volume":"3","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe 3, e944\u2013e955 (2022).","journal-title":"Lancet Microbe"},{"key":"8511_CR83","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S1473-3099(23)00005-1","volume":"23","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents. Lancet Infect. Dis. 23, 276\u2013277 (2023).","journal-title":"Lancet Infect. Dis."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08511-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:25:05Z","timestamp":1743319505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08511-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":83,"journal-issue":{"issue":"8056","published-print":{"date-parts":[[2025,3,27]]}},"alternative-id":["8511"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-08511-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.B. has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}